Annual Report Reveals Going Concern Warning, Significant Losses, and Heavy Dilutive Financing
NWBO is trading near its 52-week low of $0.195 (2.5% above the low).
Summary
Northwest Biotherapeutics' 10-K reveals a 'going concern' warning, substantial net losses, and a reliance on highly dilutive financing, despite a strategic acquisition to bolster manufacturing capabilities.
Key Events · Financing and Capital Events · NWBO
-
Going Concern Warning Issued
The independent auditors issued a 'going concern' opinion, indicating substantial doubt about the company's ability to continue operations due to recurring losses and negative cash flows.
-
Significant Net Loss and Cash Burn
Reported a net loss of $60.2 million for the year ended December 31, 2025, and used $44.8 million in cash from operating activities during the same period.
-
Heavy Dilutive Financing Activities
Issued approximately 96.7 million common shares (fair value $25.9 million) to settle $19.7 million of debt, and 88.1 million shares for $19.3 million in cash. Additionally, issued $8.0 million in new convertible notes (June and November Yorkville Notes) with variable conversion prices, and converted $3.4 million of other convertible notes into 14.9 million shares.
-
Authorized Shares Increased
Increased authorized common stock from 1.7 billion to 2.6 billion shares in December 2025, providing significant capacity for future equity issuances.
Analysis · NWBO · Life Sciences
Northwest Biotherapeutics' annual report highlights severe financial distress, with auditors issuing a 'going concern' opinion due to persistent operating losses and negative cash flows. The company continues to rely heavily on dilutive financing, including convertible notes with variable conversion prices, which poses a significant risk of further shareholder dilution. While the acquisition of Advent BioServices is a strategic move to integrate manufacturing, the overall financial picture remains precarious, necessitating continuous capital raises in a challenging market environment.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 40.6% of the 409 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NWBO was trading at $0.20 on OTC in the Life Sciences sector, with a market capitalization of approximately $308M. The 52-week trading range was $0.20 to $0.48. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.